Bariatric surgery

Series
Surgical methods
Status
Published
Date
Number of report
038

Ask the expert

(we accept only company emails)

The report presents a summary of the reimbursement situation for bariatric surgery for morbid obesity in Europe.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

Report includes reimbursement analysis for placement of adjustable gastric band, sleeve gastrectomy, and gastric bypass.

The only reimbursement within public / statutory health insurance systems is considered.

The report includes essential information about reimbursement, including:

  • Brief country-specific overview of reimbursement system
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions on indications or scenarios for the use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • Finland
  • France
  • Germany
  • Italy
  • The Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Table of content is not available at this moment.

10

Jun 2022

On May 31, 2022, the French National Authority for Health (HAS) published the final positive opinion on the coverage of the endoscopic gastroplasty with the ENDOMINA triangulation platform under the Innovation package (Forfait innovation).

Read more

19

May 2022

On April 25, 2022, the Decision Forum for "New Method" did not prioritize any surgical procedure in the treatment of morbid obesity. Available evidence in the complete method assessment shows minor or no difference in weight loss, diabetes control, or health-related quality of life when using various surgical procedures. The comparative effect on the risk of early mortality, progression of obesity, and obesity-related comorbidities was not possible to determine. The cost differences are non-significant. Further research was recommended.

Read more

31

Jan 2022

On January 20, 2022, the Academy of Medical Royal Colleges (AoMRC) launched a consultation on the latest set of guidance (List 3) of the Evidence-based Interventions (EBI) Programme. EBI program develops guidance sets (Lists) for tests, treatments, and procedures based on recommendations from the Expert Advisory Committee and NICE assessments. Proposed List 3 covers 17 interventions across a range of medical specialties, including cardiology, ophthalmology, urology, and others. The deadline for comments submission is March 31, 2022.

Read more

02

Sep 2021

At the beginning of August 2021, the European Network for Health Technology Assessment, EUnetHTA, released a final report on the surgical procedures for the treatment of obesity. The results suggest little or no difference in the effects of different bariatric surgery procedures on weight loss and diabetes control. However, the results are based mainly on low to very low certainty evidence, with few or even single studies providing data for many of the comparisons.

Read more

10

Aug 2021

In July 2021, the Austrian Institute for Health Technology Assessment (AIHTA) published six new decision support documents and one update to a previous decision support document. The assessed topics included percutaneous left ventricular assist devices, liposuction for surgical therapy of lipoedema, triphasic biomaterial for augmentation of the osteoporotic femoral neck, endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD), allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses, and surgical interventions for the treatment of benign prostatic hyperplasia. The updated decision support document concerned implantable bulking agents for fecal incontinence.

Read more
(we accept only company emails)